Saturday 17 October 2026 Export HSCS’s income statement to Excel — free account

HeartSciences Inc.

HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.

3.02 0.16 −5.03%

Follow HSCS

Alert me

Market cap: $15.4M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 4/9
Altman Z: −27.87
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 15.41

Revenue 0.02

Net Income (10.26)

Free Cash Flow (7.12)

Net Debt (0.03)

Current Ratio 0.14

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.64)

P/S ratio 525.12

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 25.90%

Next Y EPS Growth 28.86%

Next Y revenue growth 297.67%

Next 5Y EPS Growth 40.70%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 76.37%

10-year low 10-year high

EV/Sales against its own 10 years 74.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	6	1	2	0
Receivables	—	0	—	—
Inventory	1	1	1	0
Other	0	0	0	0
	7	2	3	1

	2024	2025	2026	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	2	4	5	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	(30.01%)	(6.14%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(0.65%)

Revenue $m

	Jan	Apr	Jul	Oct	Year
’26	—	—	0	—	—
’26	—	—	0	0	0
’25	—	—	—	—	0
’24	0	—	—	0	0
’23	0	0	0	—	0
’22	0	0	0	—	0
’21	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(1)	—	—	—	—
’26	(2)	(2)	(1)	(2)	(7)
’25	(2)	(2)	(2)	(2)	(7)
’24	(1)	(1)	(2)	(2)	(6)
’23	(2)	(1)	(1)	(2)	(6)
’22	(1)	(1)	(1)	(1)	(4)
’21	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(2)	—	—	—	—
’26	(2)	(2)	(1)	(2)	(7)
’25	(2)	(2)	(2)	(2)	(7)
’24	(1)	(1)	(2)	(2)	(6)
’23	(2)	(1)	(1)	(2)	(6)
’22	(1)	(1)	(1)	(1)	(4)
’21	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Jul	Oct	Jan	Apr	Year
’26	(0.86)	—	—	—	—
’26	(1.58)	(0.85)	(0.63)	(0.88)	(3.48)
’25	(2.64)	(2.27)	(2.57)	(1.88)	(9.34)
’24	(13.00)	(16.00)	(3.00)	0.00	(19.00)
’23	(28.00)	(22.00)	(16.00)	(16.00)	(80.00)
’22	(15.14)	(31.23)	(37.26)	(61.84)	(145.48)
’21	—	—	—	—	(74.00)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	—	—	78.00	14.50	2.36	2.01	1.63	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	—	—	600.00	395.00	18.50	6.47	5.25
People
People	Employees	—	—	—	—	13	12	12	15	15	14
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	0	0	0
	Gross margin, %	—	—	—	(71.81)	58.20	45.14	46.15	67.20	56.82	60.47
	EBT	—	—	—	(4)	(2)	(5)	(6)	(7)	(9)	(9)
	EBT margin, %	—	—	—	(5,936.29)	(9,578.91)	(33,529.86)	(122,198.08)	(35,511.83)	(199,209.09)	(212,602.33)
	Net income	—	—	—	(4)	(2)	(5)	(6)	(7)	(9)	(9)
	Depreciation	—	—	—	0	0	0	0	0	0	1
Per share, $
Per share, $	Revenue	—	—	—	0.01	0.77	0.43	0.07	0.05	0.00	0.00
	Earnings	—	—	—	(0.47)	(74.00)	(145.48)	(80.00)	(19.00)	(9.34)	(3.48)
	Cash flow	—	—	—	(0.48)	(74.09)	(109.76)	(72.62)	(17.22)	(7.90)	(2.83)
	Capex	—	—	—	0.00	(0.02)	(0.06)	(0.23)	(0.36)	(0.03)	(0.02)
	Free cash flow	—	—	—	(0.48)	(74.11)	(109.82)	(72.85)	(17.58)	(7.93)	(2.85)
	Book value	—	—	—	0.04	(57.69)	(182.40)	2.90	20.76	0.22	0.09
	Shares, m	—	—	—	8	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	0.00	0.00	722.34	157.43	159.88	223.56
	P/B	—	—	—	0.00	0.00	0.00	29.18	0.44	16.08	22.73
	EV/Sales	—	—	—	0.00	0.00	0.00	624.44	(88.72)	121.11	180.54
	EV/FCF	—	—	—	(2.58)	(2.58)	(2.58)	(1.00)	0.30	(0.33)	(0.55)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(4)	(2)	(4)	(6)	(6)	(7)	(7)
	Capex	—	—	—	0	0	0	0	0	0	0
	Free cash flow	—	—	—	(4)	(2)	(4)	(6)	(6)	(7)	(7)
Balance, $m
Balance, $m	Working capital	—	—	—	0	1	(2)	1	6	(2)	(2)
	Total debt	—	—	—	1	3	4	1	—	—	—
	Net debt	—	—	—	0	2	4	(1)	(6)	(1)	(2)
	Shareholders’ equity	—	—	—	0	(2)	(6)	0	7	0	0
Returns, %
Returns, %	ROA	—	—	—	0.00	(126.29)	(240.41)	(236.37)	(103.28)	(127.72)	(192.75)
	ROIC	—	—	—	0.00	(1,369.82)	0.00	0.00	(261.05)	0.00	0.00
	ROE	—	—	—	0.00	307.49	121.22	218.13	(175.04)	(233.06)	(4,252.05)

Negative figures in brackets.

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 1 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PAVM PAVmed Inc.	$19.4M	— (loss-making)	— (loss-making)	+450.00% (above 0%: growing)	n/m	−125.63% (below 0%: shrinking)	(269.70%)	(21,278.79%)	Compare
BDMD Baird Medical Investment Holdings Limited	$19.2M	— (loss-making)	—	—	n/m	−598.12% (below 0%: shrinking)	—	—	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)	Compare
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
Median of peers	$15.6M	—	—	+14.60%	—	+0.76%	40.90%	(126.60%)

All 149 Medical Devices stocks →

HeartSciences Inc. (HSCS) key facts

Concern: HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025.
HeartSciences Inc. (HSCS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HSCS traded at $3.02, a market capitalization of $15.4 million.
Return on equity was −4,252.1% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −27.87 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.